Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yi-Qi Yang-Xue Tong-Luo Fang is a Traditional Chinese Medicine (TCM) herbal formula developed by the TCM Department of Peking University Cancer Hospital & Institute. It is specifically designed for the management of chemotherapy-induced peripheral neuropathy (CIPN), a common and dose-limiting toxicity associated with taxane-based agents like paclitaxel. The formula is administered topically as a hand and foot bath. According to TCM principles, the formula aims to tonify Qi (Yi-Qi), nourish blood (Yang-Xue), and unblock the collaterals (Tong-Luo) to alleviate neuropathic symptoms such as numbness and paresthesia. It is currently being evaluated in Phase 4 clinical trials to assess its efficacy and safety compared to standard neurotrophic agents like methylcobalamin, with a focus on improving the quality of life for cancer patients, particularly those with breast cancer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yi-Qi Yang-Xue Tong-Luo Fang.